These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 1553805)

  • 1. [Prospective randomized multicenter phase III study of treatment of hormone refractory prostatic cancer: mitomycin C vs. 4-epirubicin vs. estramustine phosphate].
    Weissbach L
    Urologe A; 1992 Jan; 31(1):62. PubMed ID: 1553805
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study.
    Tveter KJ; Hagen S; Holme I; Klepp O; Kloster SE; Muri O; Poulsen C; Sander S; Sivertsen S; Urnes T
    Scand J Urol Nephrol; 1990; 24(4):243-7. PubMed ID: 2148830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone-resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose epirubicin treatments.
    Elomaa I; Kellokumpu-Lehtinen P; Rannikko S; Alfthan O
    Eur Urol; 1991; 19(1):12-5. PubMed ID: 1706666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epirubicin and medroxyprogesterone acetate versus estramustine phosphate in hormone-resistant prostatic cancer: a prospective randomized study.
    Anderström C; Eddeland A; Folmerz P; Hansson R; Milles S; Zachrisson B
    Eur Urol; 1995; 27(4):301-5. PubMed ID: 7656906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study.
    Nilsson S; Strang P; Ginman C; Zimmermann R; Edgren M; Nordström B; Ryberg M; Kälkner KM; Westlin JE
    J Pain Symptom Manage; 2005 Apr; 29(4):352-7. PubMed ID: 15857738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.
    Hudes GR; Obasaju C; Chapman A; Gallo J; McAleer C; Greenberg R
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):6-11. PubMed ID: 7597435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
    Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized controlled study on the treatment of stage C and stage D prostatic cancer with estracyt in combination with other chemotherapeutic agents.
    Akaza H; Isurugi K; Oishi Y; Kitajima K; Sawamura Y; Baba S; Yoshida K; Otani M; Harada M; Gunji A
    Jpn J Clin Oncol; 1988 Dec; 18(4):343-55. PubMed ID: 2462651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.
    Berruti A; Fara E; Tucci M; Tarabuzzi R; Mosca A; Terrone C; Gorzegno G; Fasolis G; Tampellini M; Porpiglia F; De Stefanis M; Fontana D; Bertetto O; Dogliotti L;
    Urol Oncol; 2005; 23(1):1-7. PubMed ID: 15885575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ; Smith DC
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of estramustine phosphate on free androgens. A comparative study of the effect of orchiectomy and estramustine phosphate on free androgens in patients with prostatic cancer.
    Van Poppel H; Werbrouck PW; Baert L
    Acta Urol Belg; 1990; 58(4):89-95. PubMed ID: 2093302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly epirubicin in patients with hormone refractory prostatic cancer--a two-year follow-up.
    Burk K; Schultze-Seemann W; Jonas D; Rodeck G
    Prog Clin Biol Res; 1989; 303():277-85. PubMed ID: 2674990
    [No Abstract]   [Full Text] [Related]  

  • 13. Continuous versus intermittent oral therapy with estramustine phosphate (Estracyt).
    Vahlensieck W; Wegner G
    Scand J Urol Nephrol Suppl; 1980; 55():147-9. PubMed ID: 6938018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. French multicenter study on the use of estramustine phosphate versus diethylstilbestrol.
    Hauchecorne J
    Prog Clin Biol Res; 1987; 243B():229-34. PubMed ID: 3309983
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of hormone-refractory prostate cancer with estramustine phosphate].
    Morote J; López-Pacios MA; Ahmad A; Vila J; de Torres JA
    Actas Urol Esp; 1991; 15(5):421-4. PubMed ID: 1725472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estramustine-based chemotherapy.
    Hudes G
    Semin Urol Oncol; 1997 Feb; 15(1):13-9. PubMed ID: 9050135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
    Samelis GF; Kalofonos H; Adamou A; Kosmides P; Skarlos D; Aravantinos G; Kiamouris C; Adimchi O; Fountzilas G; Dimopoulos AM
    Urology; 2005 Aug; 66(2):382-5. PubMed ID: 16098366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer].
    Kimura M; Sasagawa T; Tomita Y; Katagiri A; Morishita H; Saito T; Tanikawa T; Kawasaki T; Saito K; Nishiyama T; Kasahara T; Hara N; Takahashi K
    Hinyokika Kiyo; 2003 Dec; 49(12):709-14. PubMed ID: 14978952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.